Tiziana Life Sciences Ltd
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| TLSA | ZURA | IMUX | CHRS | COYA | HURA | |
|---|---|---|---|---|---|---|
| Market cap | 138.71M | 383.32M | 108.47M | 159.14M | 112.83M | 121.08M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -6.1 | -5.8 | -3.3 | -1.6 | -2.6 | -3.1 |
| Price/book | — | 1.9 | 0.9 | 2.6 | 2.6 | 6.6 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −44.13% | +3.63% | −8.49% | −38.15% | −18.32% | −19.34% |
| Today | −8.40% | 0.00% | −2.93% | −3.74% | −2.83% | −3.06% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All TLSA news ›Tiziana Life Sciences (NASDAQ:TLSA) Stock Rating Cut to “Strong Sell” at Wall Street Zen
Posted by Michael Walen on Oct 4th, 2026 Wall Street Zen cut shares of Tiziana Life Sciences (NASDAQ:TLSA – Free Report) from a sell rating to a strong sell rating in a research note issued to investors on Saturday morning,Wall Street Zen…
Market movers: HPE, Boeing, Salesforce, Tiziana Life Sciences...
MongoDB Inc (NASDAQ:MDB) raised its long-term growth targets at its investor day, with Bank of America saying the event was a net positive and maintaining its Buy rating on the stock. For fiscal 2028 to 2030, the database company now…
Tiziana Life Sciences seeks FDA orphan drug status for nasal MSA therapy
Proactive has a commercial relationship with Tiziana Life Sciences Ltd. This article was produced independently under Proactive's Editorial Standards Policy. Tiziana Life Sciences Ltd (NASDAQ:TLSA) has asked the US Food and Drug…
Tiziana Life Sciences seeks FDA orphan drug sta...
Tiziana Life Sciences has applied to the US FDA for orphan drug designation for its intranasal foralumab to treat multiple system atrophy (MSA), a rare and rapidly progressing neurodegenerative disorder with no approved disease-modifying…
Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
TradingView Tiziana Life Sciences - Submits Request To FDA For Orphan Drug Designation For Intranasal Foralumab For Msa
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
proactiveinvestors.com3
-
pluang.com1
-
quiverquant.com1
-
themarketsdaily.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.